Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin‐C and bacillus Calmette‐Guérin in patients with high‐risk bladder cancer
- 22 January 2007
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 99 (4), 817-820
- https://doi.org/10.1111/j.1464-410x.2006.06706.x
Abstract
To report the 10-year follow-up of a study randomizing between instillations of bacillus Calmette-Guérin (BCG) and mitomycin-C (MMC) for treating high-risk and not muscle-invasive urinary bladder cancer to assess progression, the need for more aggressive treatment and survival (cancer-specific and overall), as many of the published studies comparing different treatments for disease that is not muscle-invasive have a short follow-up. Between 1987 and 1992, 261 patients were included; they had frequently recurring Ta/T1G1-G2, T1G3 or primary Tis-dysplasia. The patients were randomized to treatment with either 40 mg of MMC or 120 mg of BCG (Danish strain 1331) given weekly for 6 weeks, then monthly up to a year and finally every third month for a further year. The 250 evaluable patients were followed using hospital files and national registers on causes of death. The median follow-up for survivors was 123 months. The disease progressed in 58 (23%) of the patients, 34 in the MMC group and 24 in the BCG group (P = 0.26). Of the 140 patients who died, 68 were in the BCG and 72 in the MMC group (log-rank P = 0.98); most (95, 68%) died from other causes. Based on the follow-up of the present patients it cannot be concluded that the drugs originally administered, MMC or BCG, differed in their effect on progression, need for subsequent treatment or survival.Keywords
This publication has 12 references indexed in Scilit:
- Management of stage T1 tumors of the bladder: International Consensus PanelUrology, 2005
- The Influence of Intravesical Therapy on Progression of Superficial Transitional Cell Carcinoma of the BladderAmerican Journal of Clinical Oncology, 2004
- Intravesical bacillus Calmette‐Guérin is superior to mitomycin C in reducing tumour recurrence in high‐risk superficial bladder cancer: a meta‐analysis of randomized trialsBJU International, 2004
- Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical TrialsJournal of Urology, 2002
- Guidelines on Bladder CancerEuropean Urology, 2002
- Estimating the world cancer burden: Globocan 2000International Journal of Cancer, 2001
- Methods to Improve Efficacy of Intravesical Mitomycin C: Results of a Randomized Phase III TrialJNCI Journal of the National Cancer Institute, 2001
- BLADDER CANCER CLINICAL GUIDELINES PANEL SUMMARY REPORT ON THE MANAGEMENT OF NONMUSCLE INVASIVE BLADDER CANCER (STAGES Ta, T1 AND TIS)Journal of Urology, 1999
- 5-YEAR FOLLOWUP OF A RANDOMIZED PROSPECTIVE STUDY COMPARING MITOMYCIN C AND BACILLUS CALMETTE-GUERIN IN PATIENTS WITH SUPERFICIAL BLADDER CARCINOMAJournal of Urology, 1999
- A Randomized Prospective Study Comparing Long-Term Intravesical Instillations of Mitomycin C and Bacillus Calmette-Guerin in Patients with Superficial Bladder CarcinomaJournal of Urology, 1996